PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Two New SensoLyte® Cathepsin L Assay Kits - AnaSpec is pleased to announce the release of two new SensoLyte® assay kits for the measurement of Cathepsin L activity the SensoLyte® 520 and Rh110 Cathepsin L Assay Kits - AnaSpec.com
AnaSpec Introduces Two New SensoLyte® Cathepsin L Assay Kits

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2013/02/07 - AnaSpec is pleased to announce the release of two new SensoLyte® assay kits for the measurement of Cathepsin L activity the SensoLyte® 520 and Rh110 Cathepsin L Assay Kits - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The former utilizes a FRET (fluorescent resonance energy transfer)-based peptide substrate and the latter, a fluorophore labeled substrate. Both substrates emit at the green emission wavelength of 520 nm (excitation at 490 nm); consequently, background fluorescence is lower. As well, both substrates provide minimal (if any) cross-reaction with other cathepsins.

The FRET peptide in the SensoLyte® 520 kit employs the QXL™ 520/HiLyte Fluor™ 488 pair for optimal quenching of the intact substrate. Hydrolysis of the FRET substrate by active Cathepsin L results in increase of HiLyte Fluor™ 488 fluorescence. Additionally, the fluorescent signal from HiLyte Fluor™ 488 is stable at low pH, the pH at which Cathepsin L activity is optimal. This homogeneous assay can be used for the detection of Cathepsin L activity in biological samples or in purified enzyme preparations. The SensoLyte® Rh110 Cathepsin L Activity Assay Kit provides a convenient assay for screening Cathepsin L inhibitors or assay of enzyme activity using Rh110 (rhodamine 110). Upon cleavage by Cathepsin L, this substrate generates Rh110 emitting bright green fluorescence.

Cathepsin L, a lysosomal endopeptidase, is a member of the papain-like family of cysteine proteinases (1). It is involved in the promotion of tumor cell invasion (2), antigen processing and turnover of intracellular and secreted proteins (3). It also plays a major role in growth regulation, bone resorption and metastasis (4, 5).

References:
1. Barrett, A.J. et al. Meth Enzymol 80, 535 (1981).
2. Gottesman, M.M. et al. Biochem 20, 1659 (1981).
3. Ishidoh, K. et al. Biochem Biophys Res Commun 217, 624 (1995).
4. Kane, S.E. et al. Semin Cancer Biol 1, 127 (1990).
5. Kirschke, H. et al. Eur J Cancer 36, 787 (2000).

About AnaSpec, EGT Group

AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutions™ for worldwide life science research. AnaSpec (anaspec.com) offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCR MasterMixes. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Two New SensoLyte® Cathepsin L Assay Kits

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560 cecilia[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)